Analysis of adverse drug reactions of Osimertinib in the 2nd‐line treatment of EGFR mutant advanced nonsmall cell lung cancer
Abstract The aim was to analyze the clinical characteristics of adverse drug reactions (ADRs) induced by Osimertinib and their effects on the prognosis, so as to further provide reference for clinical medication. This was a retrospective study, and 66 nonsmall cell lung cancer (NSCLC) patients who h...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | Precision Medical Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/prm2.12075 |
| _version_ | 1817999838219862016 |
|---|---|
| author | Yingying Jiang Yue Shi Zihan Wang Hang Li Zhitong Wang Kang He Yuxin Ma Jingjing Xue Yumeng Shi Jianwei Lu Meiqi Shi Bo Shen Guoren Zhou Xiaohua Wang Cheng Chen Jifeng Feng |
| author_facet | Yingying Jiang Yue Shi Zihan Wang Hang Li Zhitong Wang Kang He Yuxin Ma Jingjing Xue Yumeng Shi Jianwei Lu Meiqi Shi Bo Shen Guoren Zhou Xiaohua Wang Cheng Chen Jifeng Feng |
| author_sort | Yingying Jiang |
| collection | DOAJ |
| description | Abstract The aim was to analyze the clinical characteristics of adverse drug reactions (ADRs) induced by Osimertinib and their effects on the prognosis, so as to further provide reference for clinical medication. This was a retrospective study, and 66 nonsmall cell lung cancer (NSCLC) patients who had ADR in the 2nd‐line treatment with Osimertinib from January 2017 to December 2018 were included. Clinical characteristics and survival in subgroups of Osimertinib‐related ADRs were analyzed. The majority of patients who developed ADRs after the 2nd‐line treatment of Osimertinib were mainly middle‐aged and elderly women. Osimertinib‐related ADRs were mainly found in the skin, respiratory and digestive systems. The most common ADRs were rash (69.70%), diarrhea (66.67%), stomatitis (54.55%), and fatigue (51.52%). The degree of Osimertinib‐related ADRs was tolerable. Only seven patients experienced grade 3 ADRs, all of which involved the skin system. Exactly 92.42% of patients had more than two adverse reactions. The median PFS was influenced by the type, quantity, and severity of Osimertinib‐related ADRs. Osimertinib‐related ADRs are closely related to the prognosis of patients so that more attention should be paid to monitoring the occurrence of ADRs in clinical use of Osimertinib, especially ADRs in the skin, respiratory system and digestive system. |
| first_indexed | 2024-04-14T03:14:26Z |
| format | Article |
| id | doaj.art-17e1e4e6e3054a78b238d56a1cfc8e29 |
| institution | Directory Open Access Journal |
| issn | 2642-2514 |
| language | English |
| last_indexed | 2024-04-14T03:14:26Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Precision Medical Sciences |
| spelling | doaj.art-17e1e4e6e3054a78b238d56a1cfc8e292022-12-22T02:15:31ZengWileyPrecision Medical Sciences2642-25142022-06-01112698110.1002/prm2.12075Analysis of adverse drug reactions of Osimertinib in the 2nd‐line treatment of EGFR mutant advanced nonsmall cell lung cancerYingying Jiang0Yue Shi1Zihan Wang2Hang Li3Zhitong Wang4Kang He5Yuxin Ma6Jingjing Xue7Yumeng Shi8Jianwei Lu9Meiqi Shi10Bo Shen11Guoren Zhou12Xiaohua Wang13Cheng Chen14Jifeng Feng15The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital Jiangsu Institute of Cancer Research Nanjing Jiangsu ChinaThe Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital Jiangsu Institute of Cancer Research Nanjing Jiangsu ChinaSchool of Life Science Nantong University Nantong Jiangsu ChinaDepartment of Chronic Disease Epidemiology Yale School of Public Health New Haven Connecticut USANanjing Medical University Nanjing Jiangsu ChinaThe Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital Jiangsu Institute of Cancer Research Nanjing Jiangsu ChinaThe Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital Jiangsu Institute of Cancer Research Nanjing Jiangsu ChinaNanjing Medical University Nanjing Jiangsu ChinaNanjing Medical University Nanjing Jiangsu ChinaDepartment of Oncology, Jiangsu Cancer Hospital Jiangsu Institute of Cancer Research Nanjing Jiangsu ChinaDepartment of Oncology, Jiangsu Cancer Hospital Jiangsu Institute of Cancer Research Nanjing Jiangsu ChinaDepartment of Oncology, Jiangsu Cancer Hospital Jiangsu Institute of Cancer Research Nanjing Jiangsu ChinaDepartment of Oncology, Jiangsu Cancer Hospital Jiangsu Institute of Cancer Research Nanjing Jiangsu ChinaDepartment of Oncology, Jiangsu Cancer Hospital Jiangsu Institute of Cancer Research Nanjing Jiangsu ChinaDepartment of Radiotherapy Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research Nanjing Jiangsu ChinaDepartment of Oncology, Jiangsu Cancer Hospital Jiangsu Institute of Cancer Research Nanjing Jiangsu ChinaAbstract The aim was to analyze the clinical characteristics of adverse drug reactions (ADRs) induced by Osimertinib and their effects on the prognosis, so as to further provide reference for clinical medication. This was a retrospective study, and 66 nonsmall cell lung cancer (NSCLC) patients who had ADR in the 2nd‐line treatment with Osimertinib from January 2017 to December 2018 were included. Clinical characteristics and survival in subgroups of Osimertinib‐related ADRs were analyzed. The majority of patients who developed ADRs after the 2nd‐line treatment of Osimertinib were mainly middle‐aged and elderly women. Osimertinib‐related ADRs were mainly found in the skin, respiratory and digestive systems. The most common ADRs were rash (69.70%), diarrhea (66.67%), stomatitis (54.55%), and fatigue (51.52%). The degree of Osimertinib‐related ADRs was tolerable. Only seven patients experienced grade 3 ADRs, all of which involved the skin system. Exactly 92.42% of patients had more than two adverse reactions. The median PFS was influenced by the type, quantity, and severity of Osimertinib‐related ADRs. Osimertinib‐related ADRs are closely related to the prognosis of patients so that more attention should be paid to monitoring the occurrence of ADRs in clinical use of Osimertinib, especially ADRs in the skin, respiratory system and digestive system.https://doi.org/10.1002/prm2.12075adverse drug reactionsnonsmall cell lung cancerOsimertinib |
| spellingShingle | Yingying Jiang Yue Shi Zihan Wang Hang Li Zhitong Wang Kang He Yuxin Ma Jingjing Xue Yumeng Shi Jianwei Lu Meiqi Shi Bo Shen Guoren Zhou Xiaohua Wang Cheng Chen Jifeng Feng Analysis of adverse drug reactions of Osimertinib in the 2nd‐line treatment of EGFR mutant advanced nonsmall cell lung cancer Precision Medical Sciences adverse drug reactions nonsmall cell lung cancer Osimertinib |
| title | Analysis of adverse drug reactions of Osimertinib in the 2nd‐line treatment of EGFR mutant advanced nonsmall cell lung cancer |
| title_full | Analysis of adverse drug reactions of Osimertinib in the 2nd‐line treatment of EGFR mutant advanced nonsmall cell lung cancer |
| title_fullStr | Analysis of adverse drug reactions of Osimertinib in the 2nd‐line treatment of EGFR mutant advanced nonsmall cell lung cancer |
| title_full_unstemmed | Analysis of adverse drug reactions of Osimertinib in the 2nd‐line treatment of EGFR mutant advanced nonsmall cell lung cancer |
| title_short | Analysis of adverse drug reactions of Osimertinib in the 2nd‐line treatment of EGFR mutant advanced nonsmall cell lung cancer |
| title_sort | analysis of adverse drug reactions of osimertinib in the 2nd line treatment of egfr mutant advanced nonsmall cell lung cancer |
| topic | adverse drug reactions nonsmall cell lung cancer Osimertinib |
| url | https://doi.org/10.1002/prm2.12075 |
| work_keys_str_mv | AT yingyingjiang analysisofadversedrugreactionsofosimertinibinthe2ndlinetreatmentofegfrmutantadvancednonsmallcelllungcancer AT yueshi analysisofadversedrugreactionsofosimertinibinthe2ndlinetreatmentofegfrmutantadvancednonsmallcelllungcancer AT zihanwang analysisofadversedrugreactionsofosimertinibinthe2ndlinetreatmentofegfrmutantadvancednonsmallcelllungcancer AT hangli analysisofadversedrugreactionsofosimertinibinthe2ndlinetreatmentofegfrmutantadvancednonsmallcelllungcancer AT zhitongwang analysisofadversedrugreactionsofosimertinibinthe2ndlinetreatmentofegfrmutantadvancednonsmallcelllungcancer AT kanghe analysisofadversedrugreactionsofosimertinibinthe2ndlinetreatmentofegfrmutantadvancednonsmallcelllungcancer AT yuxinma analysisofadversedrugreactionsofosimertinibinthe2ndlinetreatmentofegfrmutantadvancednonsmallcelllungcancer AT jingjingxue analysisofadversedrugreactionsofosimertinibinthe2ndlinetreatmentofegfrmutantadvancednonsmallcelllungcancer AT yumengshi analysisofadversedrugreactionsofosimertinibinthe2ndlinetreatmentofegfrmutantadvancednonsmallcelllungcancer AT jianweilu analysisofadversedrugreactionsofosimertinibinthe2ndlinetreatmentofegfrmutantadvancednonsmallcelllungcancer AT meiqishi analysisofadversedrugreactionsofosimertinibinthe2ndlinetreatmentofegfrmutantadvancednonsmallcelllungcancer AT boshen analysisofadversedrugreactionsofosimertinibinthe2ndlinetreatmentofegfrmutantadvancednonsmallcelllungcancer AT guorenzhou analysisofadversedrugreactionsofosimertinibinthe2ndlinetreatmentofegfrmutantadvancednonsmallcelllungcancer AT xiaohuawang analysisofadversedrugreactionsofosimertinibinthe2ndlinetreatmentofegfrmutantadvancednonsmallcelllungcancer AT chengchen analysisofadversedrugreactionsofosimertinibinthe2ndlinetreatmentofegfrmutantadvancednonsmallcelllungcancer AT jifengfeng analysisofadversedrugreactionsofosimertinibinthe2ndlinetreatmentofegfrmutantadvancednonsmallcelllungcancer |